

Screening Phase (4 weeks)
Open-Label Phase (8 weeks)
Double-blind Retreatment Phase (40 weeks)
Responders
S
S
S
S
S
P
S
P
S
S
Sage-217 30 mg
Randomization
Compound 1 or Placebo
Post-Treatment, Follow-up Period
2 weeks
6 weeks

FIG. 1



KEY
(1) Placebo (n=157)
(2) Compound 1: 20mg (n=159)
(3) Compound 1: 30mg (n=166)
*p<0.05 vs. placebo
HAM-D-17 Change from Baseline
0
-2
-4
-6
-8
-10
-12
-14
Day
0
3
8
12
15
-6.7
-7.1
-7.8
-8.2
-8.4
-9.9
-10.2
-11.2
-11.5
-9.9
-12.0
-12.6
*
*
*
Compound 1 30mg
• -1.6; p=0.016
Compound 1 30mg
• -2.1; p=0.008
Compound 1 30mg
• -2.1; p=0.018
Compound 1 30mg
• -1.4; p=0.115
(1)
(2)
(3)

FIG. 2



KEY
(1) Primary analysis
(2) Patients with measurable drug concentrations
(3) Patients with HAM-D≥24
(4) Patients with measurable drug concentrations and HAM-D≥24
*p<0.05 vs. matched placebo
**p<0.01 vs. matched placebo
HAM-D-17 Change from Baseline
-8
-9
-10
-11
-12
-13
-14
-15
3
8
12
15
Day
(1)
(2)
(3)
(4)

FIG. 3



Treatment Period
Double-blind Follow-up Period
Follow-up Period; Interim Analysis
KEY
(1) Primary analysis
(2) Patients with measurable drug concentrations
(3) Patients with HAM-D≥24
(4) Patients with measurable drug concentrations and HAM-D≥24
HAM-D-17 Change from Baseline
-8
-9
-10
-11
-12
-13
-14
-15
-16
3
15
21
35
42
70
128
182
Day
(1)
(2)
(3)
(4)

FIG. 4